Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

EHA 2026

11 - 14 Jun 2026
Stockholmsmässan, Stockholm, Sweden
Videos
News
First-in-class switchable allogeneic CAR-T therapy shows promising activity in...
Prof Martin Wermke - National Center for Tumor Diseases, Dresden, Germany
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML ( Prof Martin Wermke - National Center for Tumor Diseases, Dresden, Germany )
22 Jun 2026
Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular...
Dr Benoit Tessoulin - CHU de Nantes, Nantes, France
Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups ( Dr Benoit Tessoulin - CHU de Nantes, Nantes, France )
22 Jun 2026
Epcoritamab improves progression-free survival in relapsed or refractory large...
Prof Christopher Fox - University of Nottingham, Nottingham, UK
Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma ( Prof Christopher Fox - University of Nottingham, Nottingham, UK )
22 Jun 2026
Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...
Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
20 Jun 2026
Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1...
Dr Chiara Sartor - University of Bologna, Bologna, Italy
Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure ( Dr Chiara Sartor - University of Bologna, Bologna, Italy )
20 Jun 2026
DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed...
Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA
DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma ( Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA )
20 Jun 2026
Favezelimab plus pembrolizumab improves progression-free survival in PD-1...
Dr Guilherme Perini - Hospital Israelita Albert Einstein, São Paulo, Brazil
Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma ( Dr Guilherme Perini - Hospital Israelita Albert Einstein, São Paulo, Brazil )
19 Jun 2026
First-in-human study of in vivo CAR-T therapy shows promising activity in...
Dr Ying Huang - CEO, Legend Biotech
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma ( Dr Ying Huang - CEO, Legend Biotech )
19 Jun 2026
Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light...
Prof Ashutosh Wechalekar - University College London Hospitals, London, UK
Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis ( Prof Ashutosh Wechalekar - University College London Hospitals, London, UK )
19 Jun 2026
CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R...
Prof Liang Wang - Beijing Tongren Hospital, Beijing, China
CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma ( Prof Liang Wang - Beijing Tongren Hospital, Beijing, China )
19 Jun 2026
Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute...
Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston...
Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia ( Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2026
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor...
Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation ( Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany )
18 Jun 2026
Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue...
Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA)...
Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia ( Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy )
18 Jun 2026
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL...
Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL ( Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA )
18 Jun 2026
Selinexor plus ruxolitinib improves spleen response and survival in Janus...
Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis ( Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK )
18 Jun 2026
Fatigue in adult ITP is common despite adequate platelet counts and minimal...
Prof David Kuter - Harvard Medical School, Boston, USA
Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding ( Prof David Kuter - Harvard Medical School, Boston, USA )
18 Jun 2026
Surovatamig plus rituximab induces high complete response rates in previously...
Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )
18 Jun 2026
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in...
Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026
CLL TIM risk model predicts infection and treatment need in newly diagnosed...
Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia ( Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark )
18 Jun 2026
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL
Prof Anthony Moorman - Newcastle University, Newcastle, UK
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
18 Jun 2026
Epcoritamab induces deep and durable responses in chemotherapy-ineligible...
Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse...
Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell...
Prof Marek Trněný - Charles University, Prague, Czechia
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas ( Prof Marek Trněný - Charles University, Prague, Czechia )
18 Jun 2026
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving...
Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival ( Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
18 Jun 2026

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation